Sandoz Fights Amgen's Bid To Halt 1st Biosimilar Launch
Sandoz Inc. urged the Federal Circuit to deny Amgen Inc.'s emergency bid to bar Sandoz's launch of the first-ever biosimilar drug under the Affordable Care Act, saying Friday the district court...To view the full article, register now.
Already a subscriber? Click here to view full article